Clinical proteomics: Current techniques and potential applications in the elderly

Maturitas

Volumn 68, Issue 3, 2011, Pages 233-244

  Siwy, J ^a   Vlahou, A ^b   Zimmerli, L U ^c   Zurbig P ^a   Schiffer, E ^a  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Ageing; Coronary artery disease; Diabetic nephropathy; Neoplasia; Proteomics

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; PROTEOME; TUMOR MARKER;

AGING; BIOINFORMATICS; BLADDER CANCER; CANCER GROWTH; CAPILLARY ELECTROPHORESIS; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DATA BASE; DEMOGRAPHY; DIABETIC NEPHROPATHY; HUMAN; INFORMATION PROCESSING; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MINING; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN MICROARRAY; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINALYSIS; VALIDATION PROCESS;

AGED; AGING; BIOLOGICAL MARKERS; CHRONIC DISEASE; GERIATRIC ASSESSMENT; HUMANS; PROTEOME; PROTEOMICS; RESEARCH DESIGN; VALIDATION STUDIES AS TOPIC;

EID: 79951955724     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.11.001     Document Type: Review

References (118)

1. Ginsburg GS, Haga SB. Translating genomic biomarkers into clinically useful diagnostics. Expert Rev Mol Diagn 2006;6(March (2)):179-91. (Pubitemid 44167147)
2. Lindon JC, Holmes E, Nicholson JK. Metabonomics and its role in drug development and disease diagnosis. Expert Rev Mol Diagn 2004;4(2):189-99. (Pubitemid 38327248)
3. Good DM, Thongboonkerd V, Novak J, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res 2007;6(October (12)):4549-55.
4. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5(August (13)):3226-45. (Pubitemid 41192032)
5. von Zur Muhlen C, Schiffer E, Zuerbig P, et al. Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J Proteome Res 2009;8(January (1)):335-45.
6. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65(January (1)):323-32. (Pubitemid 38037520)
7. Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006;7(March (3)):230-40. (Pubitemid 43286453)
8. Fiedler GM, Baumann S, Leichtle A, et al. Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2007;53(March (3)):421-8. (Pubitemid 46447938)
9. Good DM, Zurbig P, Argiles A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010;9(November (11)):2424-37.
10. Kolch W, Neususs C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005;24(March (6)):959-77. (Pubitemid 41641706)
11. Zurbig P, Renfrow MB, Schiffer E, et al. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006;27(June (11)):2111-25. (Pubitemid 43942113)
12. Stutz H. Advances in the analysis of proteins and peptides by capillary electrophoresis with matrix-assisted laser desorption/ionization and electrospray-mass spectrometry detection. Electrophoresis 2005;26(April (7-8)):1254-90. (Pubitemid 40645447)
13. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003;49(July (7)):1041-4. (Pubitemid 36751088)
14. Patterson SD, Aebersold R. Mass spectrometric approaches for the identification of gel-separated proteins. Electrophoresis 1995;16(October (10)):1791-814.
15. Wu TL. Two-dimensional difference gel electrophoresis. Methods Mol Biol 2006;328:71-95.
16. Issaq HJ. The role of separation science in proteomics research. Electrophoresis 2001;22(October (17)):3629-38.
17. Munro NP, Cairns DA, Clarke P, et al. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 2006;119(December (11)):2642-50. (Pubitemid 44691320)
18. Zerefos P, Prados J, Kossida S, Kalousis A, Vlahou A. Sample preparation and bioinformatics in MALDI profiling of urinary proteins. J Chromatogr B Analyt Technol Biomed Life Sci 2007;853(June (1-2)):20-30. (Pubitemid 46891340)
19. Qian WJ, Jacobs JM, Liu T, Camp DG, Smith RD. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics 2006;5(October (10)):1727-44. (Pubitemid 44696109)
20. Kislinger T, Gramolini AO, Maclennan DH, Emili A. Multidimensional protein identification technology (MudPIT): technical overview of a profiling method optimized for the comprehensive proteomic investigation of normal and diseased heart tissue. J Am Soc Mass Spectrom 2005;16(August (8)):1207-20. (Pubitemid 41059557)
21. Soldi M, Sarto C, Valsecchi C, et al. Proteome profile of human urine with two-dimensional liquid phase fractionation. Proteomics 2005;5(July (10)):2641-7. (Pubitemid 40966491)
22. Bakry R, Huck CW, Najam-ul-Haq M, Rainer M, Bonn GK. Recent advances in capillary electrophoresis for biomarker discovery. J Sep Sci 2007;30(February (2)):192-201. (Pubitemid 46322546)
23. Wu R, Hu L, Wang F, Ye M, Zou H. Recent development of monolithic stationary phases with emphasis on microscale chromatographic separation. J Chromatogr A 2008;1184(March (1-2)):369-92. (Pubitemid 351296217)
24. Schmitt-Kopplin P, Frommberger M. Capillary electrophoresis-mass spectrometry: 15 years of developments and applications. Electrophoresis 2003;24(December (22-23)):3837-67. (Pubitemid 38094442)
25. Theodorescu D, Fliser D, Wittke S, et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005;26(July (14)):2797-808. (Pubitemid 41078989)
26. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5(April (4)):573-88.
27. Arnett SD, Lunte CE. Investigation of the mechanism of pH-mediated stacking of anions for the analysis of physiological samples by capillary electrophoresis. Electrophoresis 2003;24(June (11)):1745-52. (Pubitemid 38088962)
28. Kiyonami R, Schoen A, Prakash A, et al. Increased selectivity, analytical precision, and throughput in targeted proteomics. Mol Cell Proteomics 2010;(July).
29. Zhang F, Dulneva A, Bailes J, Soloviev M. Affinity peptidomics: peptide selection and affinity capture on hydrogels and microarrays. Methods Mol Biol 2010;615:313-44.
30. Kozarova A, Petrinac S, Ali A, Hudson JW. Array of informatics: applications in modern research. J Proteome Res 2006;5(May (5)):1051-9. (Pubitemid 43727782)
31. Haab BB, Paulovich AG, Anderson NL, et al. A reagent resource to identify proteins and peptides of interest for the cancer community: a workshop report. Mol Cell Proteomics 2006;5(October (10)):1996-2007. (Pubitemid 44688206)
32. Aebersold R. Constellations in a cellular universe. Nature 2003;422(March (6928)):115-6. (Pubitemid 36362724)
33. Kuster B, Schirle M, Mallick P, Aebersold R. Scoring proteomes with proteotypic peptide probes. Nat Rev Mol Cell Biol 2005;6(July (7)):577-83. (Pubitemid 40943048)
34. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 2004;3(March (2)):235-44. (Pubitemid 38500990)
35. Kirkpatrick DS, Gerber SA, Gygi SP. The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 2005;35(March (3)):265-73. (Pubitemid 40255592)
36. Putz S, Reinders J, Reinders Y, Sickmann A. Mass spectrometry-based peptide quantification: applications and limitations. Expert Rev Proteomics 2005;2(June (3)):381-92. (Pubitemid 40839748)
37. Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev Proteomics 2007;4(April (2)):175-86. (Pubitemid 46588454)
38. Bronstrup M. Absolute quantification strategies in proteomics based on mass spectrometry. Expert Rev Proteomics 2004;1(December (4)):503-12. (Pubitemid 43826415)
39. Jantos-Siwy J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009;8(November (1)):268-81.
40. Dakna M, He Z, Yu WC, Mischak H, Kolch W. Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877(May (13)):1250-8.
41. Girolami M, Mischak H, Krebs R. Analysis of complex, multidimensional datasets. Drug Discov Today: Technol 2007;3(1):12-9.
42. Girolami M, Rogers S. Variational Bayesian multinomial probit regression with Gaussian process priors. Neural Comput 2006;18(8):1790-817. (Pubitemid 44036395)
43. Burges CJC. A tutorial on support vector machines for pattern recognition. Knowl Discov Data Min 1998;2(2):121-67. (Pubitemid 128695475)
44. Rasmussen CE, Williams CKI. Gaussian Processes for Machine Learning. MIT Press; 2006.
45. Mischak H, Apweiler R, Banks RE, et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007;1:148-56.
46. Zürbig P, Decramer S, Dakna M, et al. The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 2009;9(8):2108-17.
47. Jiang H, Schiffer E, Song Z, et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease 1. Proc Natl Acad Sci USA 2008;105(August (32)):11299-304.
48. Orgel LE. Ageing of clones of mammalian cells. Nature 1973;243(June (5408)):441-5.
49. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005;48(August (8)):1439-44. (Pubitemid 41175492)
50. Caramori ML, Mauer M, Diabetes nephropathy. Curr Opin Nephrol Hypertens 2003;12(May (3)):273-82.
51. Sharma K, Lee S, Han S, et al. Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005;5(July (10)):2648-55. (Pubitemid 40966492)
52. Jain S, Rajput A, Kumar Y, Uppuluri N, Arvind AS, Tatu U. Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J Assoc Phys India 2005;June (53):513-20. (Pubitemid 41282824)
53. Varghese SA, Powell TB, Budisavljevic MN, et al. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 2007;18(March (3):913-22. (Pubitemid 46434508)
54. Rao PV, Lu X, Standley M, et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007;30(March (3)):629-37. (Pubitemid 46354345)
55. Merchant ML, Perkins BA, Boratyn GM, et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009;20(September (9)):2065-74.
56. Mischak H, Kaiser T, Walden M, et al. Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond) 2004;107(November (5)):485-95. (Pubitemid 39506740)
57. Meier M, Kaiser T, Herrmann A, et al. Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications 2005;19(July (4)):223-32. (Pubitemid 40910204)
58. Rossing K, Mischak H, Dakna M, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008;19(April (7)):1283-90.
59. Kafienah W, Buttle DJ, Burnett D, Hollander AP. Cleavage of native type I collagen by human neutrophil elastase. Biochem J 1998;330(March (Pt 2)):897-902. (Pubitemid 28111994)
60. Thongboonkerd V, Barati MT, McLeish KR, et al. Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis. J Am Soc Nephrol 2004;15(March (3)):650-62. (Pubitemid 38294795)
61. Otu HH, Can H, Spentzos D, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007;30(March (3)):638-43. (Pubitemid 46354346)
62. Rossing K, Mischak H, Parving HH, et al. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005;68(July (1)):193-205. (Pubitemid 43181377)
63. Verhave JC, Hillege HL, Burgerhof JG, et al. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005;67(5):1967-73. (Pubitemid 40577733)
64. Sung HJ, Ryang YS, Jang SW, Lee CW, Han KH, Ko J. Proteomic analysis of differential protein expression in atherosclerosis. Biomarkers 2006;11(May (3)):279-90. (Pubitemid 43879074)
65. You SA, Archacki SR, Angheloiu G, et al. Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genomics 2003;13(March (1)):25-30. (Pubitemid 37129166)
66. Duran MC, Martin-Ventura JL, Mas S, et al. Characterization of the human atheroma plaque secretome by proteomic analysis. Methods Mol Biol 2007;357:141-50. (Pubitemid 350183244)
67. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117(March (3)):746-56. (Pubitemid 46348533)
68. Zimmerli LU, Schiffer E, Zürbig P, et al. Urinary proteomics biomarkers in coronary artery disease. Mol Cell Proteomics 2008;7(2):290-8. (Pubitemid 351298443)
69. Snell-Bergeon JK, Maahs DM, Ogden LG, et al. Evaluation of urinary biomarkers for coronary artery disease, diabetes, and diabetic kidney disease. Diabetes Technol Ther 2009;11(February (1)):1-9.
70. Delles C, Schiffer E, von Zur MC, et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens 2010;(September).
71. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361(March (9360)):859-64. (Pubitemid 36331852)
72. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(October (15)):909-16. (Pubitemid 17147932)
73. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56(March (2)):106-30.
74. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(March (13)):1320-8.
75. Presti Jr JC. Prostate cancer: assessment of risk using digital rectal examination, tumor grade, prostate-specific antigen, and systematic biopsy. Radiol Clin North Am 2000;38(January (1)):49-58.
76. Siddiqui E, Mumtaz FH, Gelister J. Understanding prostate cancer. J R Soc Promot Health 2004;124(September (5)):219-21. (Pubitemid 39303083)
77. Bickers B, ukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer - the post PSA era. Anticancer Res 2009;29(August (8)):3289-98.
78. You J, Cozzi P, Walsh B, et al. Innovative biomarkers for prostate cancer early diagnosis and progression. Crit Rev Oncol Hematol 2010;73(January (1)):10-22.
79. Cheung PK, Woolcock B, Adomat H, et al. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 2004;64(September (17)):5929-33. (Pubitemid 39129386)
80. Liu AY, Zhang H, Sorensen CM, Diamond DL. Analysis of prostate cancer by proteomics using tissue specimens. J Urol 2005;173(January (1)):73-8. (Pubitemid 39627676)
81. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62(July (13)):3609-14. (Pubitemid 34728833)
82. Rehman I, Azzouzi AR, Catto JW, et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004;64(December (6)):1238-43. (Pubitemid 39647082)
83. M'koma AE, Blum DL, Norris JL, et al. Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine. Biochem Biophys Res Commun 2006;(December).
84. Theodorescu D, Schiffer E, Bauer HW, et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl 2008;2(4):556-70. (Pubitemid 351566263)
85. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83(September (1)):18-29.
86. Aben KK, Kiemeney LA. Epidemiology of bladder cancer. Eur Urol 1999;36(December (6)):660-72.
87. Eissa S, Kassim S, El-Ahmady O. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opin Obstet Gynecol 2003;15(October (5)):395-403. (Pubitemid 37330384)
88. Bailey MJ. Urinary markers in bladder cancer. BJU Int 2003;91(June (9)):772-3. (Pubitemid 36724055)
89. Cajulis RS, Haines III GK, Frias-Hidvegi D, McVary K, Bacus JW. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn Cytopathol 1995;13(October (3)):214-23.
90. Goodison S, Rosser CJ, Urquidi V. Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev Proteomics 2009;6(October (5)):507-14.
91. Gaston KE, Grossman HB. Proteomic assays for the detection of urothelial cancer. Methods Mol Biol 2010;641:303-23.
92. Getzenberg RH, Konety BR, Oeler TA, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996;56(April (7)):1690-4. (Pubitemid 26104035)
93. Konety BR, Nguyen TS, Brenes G, et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000;164(September (3 Pt 1)):634-9. (Pubitemid 30637591)
94. Nielsen ME, Gonzalgo ML, Schoenberg MP, Getzenberg RH. Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. World J Urol 2006;24(November (5)):499-508. (Pubitemid 44782304)
95. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based marker of bladder cancer. Urology 2005;66(December (6)):1256-60. (Pubitemid 41797301)
96. Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J Urol 1996;155(June (6)):2113-9. (Pubitemid 26146717)
97. Celis JE, Ostergaard M, Basse B, et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 1996;56(October (20)):4782-90. (Pubitemid 26338085)
98. Ohlsson G, Moreira JM, Gromov P, Sauter G, Celis JE. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 2005;4(April (4)):570-81. (Pubitemid 40590573)
99. Iwaki H, Kageyama S, Isono T, et al. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004;95(December (12)):955-61. (Pubitemid 40089587)
100. Kageyama S, Isono T, Iwaki H, et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 2004;50(May (5)):857-66. (Pubitemid 38543664)
101. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158(April (4)):1491-502. (Pubitemid 32281313)
102. Holterman DA, Diaz JI, Blackmore PF, et al. Overexpression of alpha-defensin is associated with bladder cancer invasiveness. Urol Oncol 2006;24(2):97-108. (Pubitemid 43340166)
103. Mueller J, von Eggeling F, Driesch D, Schubert J, Melle C, Junker K. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol 2005;47(June (6)):885-93.
104. Vlahou A, Giannopoulos A, Gregory BW, et al. Protein profiling in urine for the diagnosis of bladder cancer. Clin Chem 2004;50(August (8)):1438-41. (Pubitemid 38970660)
105. Zhang YF, Wu DL, Guan M, et al. Tree analysis of mass spectral urine pro- files discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin Biochem 2004;37(9):772-9. (Pubitemid 39141118)
106. Liu W, Guan M, Wu D, et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 2005;47(April (4)):456-62. (Pubitemid 40357888)
107. Schiffer E, Vlahou A, Petrolekas A, et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res 2009;15(August (15)):4935-43.
108. Mischak H, Kolch W, Aivalotis M, et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl 2010;4(4):464-78.
109. Dihazi H, Muller GA, Lindner S, et al. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007;53(September (9)):1636-45. (Pubitemid 47340060)
110. Thongboonkerd V, Songtawee N, Sritippayawan S. Urinary proteome pro- filing using microfluidic technology on a chip. J Proteome Res 2007;6(May (5)):2011-8. (Pubitemid 46814522)
111. Bellei E, Rossi C, Lucchi L, et al. Proteomic analysis of early urinary biomarkers of renal chanegs in type 2 diabetic patients. Proteomics Clin Appl 2008;2:478-91. (Pubitemid 351566257)
112. Jiang H, Guan G, Zhang R, et al. Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy. Diabetes Metab Res Rev 2009;25(March (3)):232-41.
113. Jiang HJ, Guan GJ, Zhang R, et al. Increased urinary excretion of orosomucoid is a risk predictor of diabetic nephropathy. Nephrology 2009;14(3):332-7.
114. Thrailkill KM, Nimmo T, Bunn RC, et al. Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilin. Diabetes Care 2009;32(July (7)):1266-8.
115. Gu W, Zou L-X, Shan P-F, Chen Y-D. Analysis of urinary proteomic patterns for diabetic nephropathy by ProteinChip. Proteomics Clin Appl 2010;2(5):744-50. (Pubitemid 351772029)
116. Alkhalaf A, Zurbig P, Bakker SJ, et al. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS ONE 2010;5(10):e13421.
117. Rossing P, Zürbig P, Panagiotopoulos S, et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Nephropathy - biomarkers; 46th EASD Annual Meeting. Diabetologia 2010;53(Supplement 1):S480-1.
118. Andersen S, Mischak H, Zurbig P, Parving HH, Rossing P. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 2010 Nov 1;11(1):29.